BR0207881A - Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropina - Google Patents
Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropinaInfo
- Publication number
- BR0207881A BR0207881A BR0207881-3A BR0207881A BR0207881A BR 0207881 A BR0207881 A BR 0207881A BR 0207881 A BR0207881 A BR 0207881A BR 0207881 A BR0207881 A BR 0207881A
- Authority
- BR
- Brazil
- Prior art keywords
- crf
- function
- methods
- identifying compounds
- muscle mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Abstract
"MéTODOS PARA A IDENTIFICAçãO DE COMPOSTOS PARA REGULAR A MASSA OU A FUNçãO MUSCULAR USANDO RECEPTORES DO FATOR DE LIBERAçãO DE CORTICOTROPINA". A presente invenção refere-se a métodos de seleção para a identificação de compostos que se ligam ou ativam os receptores do fator 2 de liberação da corticotropina (CRF~ 2~R) e regulam ou regulam potencialmente a massa ou a função do músculo esqueletal in vivo. Também são descritos métodos de seleção para a identificação de compostos que prolongam ou aumentam a ativação dos CRF~ 2~Rs ou das rotas de transdução de sinal do CRF~ 2~R, aumentam o CRF~ 2~R ou aumentam a expressão do CRF. São descritas composições farmacêuticas que contêm os agonistas do CRF~ 2~R, anticorpos para o CRF~ 2~R e métodos para o aumento da massa ou função do músculo esqueletal para o tratamento da atrofia do músculo esqueletal usando o CRF~ 2~R como o alvo para a intervenção e métodos para o tratamento de distrofias musculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/799,978 US6670140B2 (en) | 2001-03-06 | 2001-03-06 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| PCT/US2002/007476 WO2002069908A2 (en) | 2001-03-06 | 2002-03-06 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207881A true BR0207881A (pt) | 2005-08-30 |
Family
ID=25177205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207881-3A BR0207881A (pt) | 2001-03-06 | 2002-03-06 | Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6670140B2 (pt) |
| EP (1) | EP1379873B1 (pt) |
| JP (2) | JP4331942B2 (pt) |
| KR (2) | KR100596991B1 (pt) |
| CN (1) | CN100520408C (pt) |
| AR (1) | AR032957A1 (pt) |
| AT (1) | ATE429242T1 (pt) |
| AU (1) | AU2002303121B2 (pt) |
| BR (1) | BR0207881A (pt) |
| CA (1) | CA2439170C (pt) |
| CZ (1) | CZ20032395A3 (pt) |
| DE (1) | DE60232063D1 (pt) |
| ES (1) | ES2325485T3 (pt) |
| HU (1) | HUP0402173A2 (pt) |
| IL (1) | IL157330A0 (pt) |
| MA (1) | MA26990A1 (pt) |
| MX (1) | MXPA03008114A (pt) |
| MY (1) | MY134755A (pt) |
| NO (1) | NO20033936L (pt) |
| NZ (1) | NZ527124A (pt) |
| PE (1) | PE20020993A1 (pt) |
| PL (1) | PL367187A1 (pt) |
| RU (1) | RU2260805C2 (pt) |
| SA (1) | SA02230159B1 (pt) |
| SK (1) | SK12132003A3 (pt) |
| TW (1) | TWI227780B (pt) |
| WO (1) | WO2002069908A2 (pt) |
| ZA (1) | ZA200305642B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1305334T3 (da) * | 2000-08-04 | 2009-02-02 | Res Dev Foundation | Urocortinproteiner og anvendelser deraf |
| AU2001289916A1 (en) * | 2000-09-22 | 2002-04-02 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US7192923B2 (en) * | 2002-01-16 | 2007-03-20 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| GB0624282D0 (en) * | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
| JP4824815B2 (ja) * | 2007-05-23 | 2011-11-30 | ファルマコーム合同会社 | リガンド親和性が改変されたｇタンパク質共役型受容体およびその利用 |
| WO2010036918A2 (en) * | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2011348068B2 (en) * | 2010-12-23 | 2016-05-05 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
| AU2012339722B2 (en) * | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| RU2517259C1 (ru) * | 2013-03-06 | 2014-05-27 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) | Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |
| JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−１抑制剤 |
| RU2568903C2 (ru) * | 2014-04-07 | 2015-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ оценки анаболического действия лекарственных препаратов |
| JP2019533021A (ja) | 2016-10-20 | 2019-11-14 | コーティーン インコーポレイテッド | 不適応のストレス応答に寄与する疾患を処置する方法 |
| CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415558A (en) | 1981-06-08 | 1983-11-15 | The Salk Institute For Biological Studies | CRF And analogs |
| AU9054582A (en) | 1982-09-29 | 1984-04-24 | Lederis, K.P., Mac Cannell, K.L.:ichikawa, T:river, J.E. | Urotensin peptides |
| US4489163A (en) | 1983-04-14 | 1984-12-18 | The Salk Institute For Biological Studies | rCRF and analogs |
| US4594329A (en) | 1984-05-14 | 1986-06-10 | The Salk Institute For Biological Studies | CRF analogs |
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| DE3703340A1 (de) * | 1987-02-04 | 1988-08-18 | Dirck Dr Med Oppermann | Pharmazeutische zubereitung zur behandlung der herzinsuffizienz |
| US4908352A (en) | 1987-09-28 | 1990-03-13 | The Salk Institute For Biological Studies | Urotensin peptides |
| US5109111A (en) | 1988-09-23 | 1992-04-28 | The Salk Institute For Biological Studies | CRF antagonists |
| US5278146A (en) | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
| CA1340964C (en) * | 1988-09-30 | 2000-04-18 | Jean E. F. Rivier | Crf analogs |
| US5235036A (en) | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
| US5493006A (en) | 1993-06-16 | 1996-02-20 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5728545A (en) | 1993-06-18 | 1998-03-17 | The Salk Institute Of Biological Studies | Cloning and recombinant production of CRF receptor (S) |
| US6495343B1 (en) * | 1993-06-18 | 2002-12-17 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
| JPH10501420A (ja) * | 1994-06-14 | 1998-02-10 | ニューロクライン バイオサイエンシズ，インコーポレイティド | 副腎皮質刺激ホルモン放出因子▲下２▼レセプター |
| EP0860501A3 (en) | 1994-06-14 | 1999-05-19 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| US5663292A (en) | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5824771A (en) | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| CA2223792A1 (en) | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| US5869450A (en) | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
| US5888811A (en) | 1996-05-23 | 1999-03-30 | Dupont Pharmaceuticals Company | Corticotropin-releasing hormone receptor |
| DE69935227T2 (de) * | 1998-07-24 | 2007-10-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Für den corticotropin-releasing-factor-typ-2-rezeptor (crfr2) spezifische antagonisten |
| DK1305334T3 (da) * | 2000-08-04 | 2009-02-02 | Res Dev Foundation | Urocortinproteiner og anvendelser deraf |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-03-06 US US09/799,978 patent/US6670140B2/en not_active Expired - Lifetime
-
2002
- 2002-03-05 TW TW091104025A patent/TWI227780B/zh not_active IP Right Cessation
- 2002-03-05 PE PE2002000176A patent/PE20020993A1/es not_active Application Discontinuation
- 2002-03-06 CA CA2439170A patent/CA2439170C/en not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011659A patent/KR100596991B1/ko not_active IP Right Cessation
- 2002-03-06 CZ CZ20032395A patent/CZ20032395A3/cs unknown
- 2002-03-06 NZ NZ527124A patent/NZ527124A/en unknown
- 2002-03-06 IL IL15733002A patent/IL157330A0/xx unknown
- 2002-03-06 DE DE60232063T patent/DE60232063D1/de not_active Expired - Lifetime
- 2002-03-06 EP EP02731122A patent/EP1379873B1/en not_active Expired - Lifetime
- 2002-03-06 JP JP2002569086A patent/JP4331942B2/ja not_active Expired - Fee Related
- 2002-03-06 PL PL02367187A patent/PL367187A1/xx not_active Application Discontinuation
- 2002-03-06 AU AU2002303121A patent/AU2002303121B2/en not_active Ceased
- 2002-03-06 MY MYPI20020802A patent/MY134755A/en unknown
- 2002-03-06 MX MXPA03008114A patent/MXPA03008114A/es active IP Right Grant
- 2002-03-06 SK SK1213-2003A patent/SK12132003A3/sk unknown
- 2002-03-06 KR KR1020067005678A patent/KR100598441B1/ko not_active IP Right Cessation
- 2002-03-06 HU HU0402173A patent/HUP0402173A2/hu unknown
- 2002-03-06 BR BR0207881-3A patent/BR0207881A/pt not_active IP Right Cessation
- 2002-03-06 ES ES02731122T patent/ES2325485T3/es not_active Expired - Lifetime
- 2002-03-06 WO PCT/US2002/007476 patent/WO2002069908A2/en active IP Right Grant
- 2002-03-06 AT AT02731122T patent/ATE429242T1/de not_active IP Right Cessation
- 2002-03-06 CN CNB028059271A patent/CN100520408C/zh not_active Expired - Fee Related
- 2002-03-06 RU RU2003129500/15A patent/RU2260805C2/ru not_active IP Right Cessation
- 2002-03-06 AR ARP020100806A patent/AR032957A1/es not_active Application Discontinuation
- 2002-06-19 SA SA02230159A patent/SA02230159B1/ar unknown
-
2003
- 2003-07-22 ZA ZA200305642A patent/ZA200305642B/en unknown
- 2003-08-07 MA MA27267A patent/MA26990A1/fr unknown
- 2003-08-27 US US10/649,852 patent/US7063954B2/en not_active Expired - Lifetime
- 2003-09-05 NO NO20033936A patent/NO20033936L/no not_active Application Discontinuation
-
2006
- 2006-04-26 US US11/412,025 patent/US7572768B2/en not_active Expired - Fee Related
-
2008
- 2008-09-01 JP JP2008224143A patent/JP2009029816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207881A (pt) | Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropina | |
| Wu et al. | Indian hedgehog is an essential component of mechanotransduction complex to stimulate chondrocyte proliferation | |
| BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
| BRPI0413490A (pt) | novos compostos | |
| BR0212809A (pt) | Inibidores de anticorpos de gdf-8 e usos dos mesmos | |
| BR0313266A (pt) | Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5 | |
| BRPI0407454A (pt) | Pirazóis e métodos de preparar e usar os mesmos | |
| BR0317430A (pt) | Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| BR9914696A (pt) | Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica | |
| WO2003057698A3 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
| BR0315598A (pt) | Anticorpos neutralizantes contra gdf-8 e usos dos mesmos | |
| BRPI0512974A (pt) | novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| BR0315143A (pt) | Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto | |
| BRPI0411020A (pt) | perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição | |
| BR0210720A (pt) | Composto e uso do mesmo | |
| BR9910458A (pt) | Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor | |
| BR0209920A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratar ansiedade, depressão ou estresse e sìndrome do intestino irritável ou doença de crohn, de detectar receptores de crf1 em uma primeira amostra biológica, de demonstrar a presença ou ausência de receptores de crf1 em uma amostra biológica e de inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem | |
| Zhang et al. | Medium-intensity treadmill exercise exerts beneficial effects on bone modeling through bone marrow mesenchymal stromal cells | |
| WO2007041502A3 (en) | Methods for determining responsiveness to cancer therapy | |
| AR038332A1 (es) | Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion | |
| BRPI0510679A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos | |
| BR0012478A (pt) | Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos | |
| BR0309406A (pt) | Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010. |